129 related articles for article (PubMed ID: 34861375)
21. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
22. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.
Abuhadra N; Sun R; Bassett RL; Huo L; Chang JT; Teshome M; Clayborn AR; White JB; Ravenberg EE; Adrada BE; Candelaria RP; Yang W; Ding Q; Symmans WF; Arun B; Damodaran S; Koenig KB; Layman RM; Lim B; Litton JK; Thompson A; Ueno NT; Piwnica-Worms H; Hortobagyi GN; Valero V; Tripathy D; Rauch GM; Moulder S; Yam C
Invest New Drugs; 2023 Jun; 41(3):391-401. PubMed ID: 37043123
[No Abstract] [Full Text] [Related]
23. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
24. Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.
van Dongen MGJ; Kok M
Ann Oncol; 2020 May; 31(5):556-557. PubMed ID: 32171753
[No Abstract] [Full Text] [Related]
25. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
Rizzo A; Palmiotti G
Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
[No Abstract] [Full Text] [Related]
27. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
28. Letter to the Editor Regarding "Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States".
Sorscher S
Adv Ther; 2023 Sep; 40(9):4111-4113. PubMed ID: 37432550
[No Abstract] [Full Text] [Related]
29. [The prospects of DNA damage repair variants guiding platinum compounds in the treatment of triple negative breast cancer].
Wang X; Yue J; Kang YK; Gao SL; Yuan P
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):68-72. PubMed ID: 35073650
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
Guven DC; Taban H; Dizdar O
J Oncol Pharm Pract; 2022 Jan; 28(1):203-204. PubMed ID: 34628993
[No Abstract] [Full Text] [Related]
31. De-escalating and escalating systemic therapy in triple negative breast cancer.
Carey LA
Breast; 2017 Aug; 34 Suppl 1():S112-S115. PubMed ID: 28690105
[TBL] [Abstract][Full Text] [Related]
32. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions.
Bianchini G; Licata L; Viale G; Gianni L
Ann Oncol; 2022 Nov; 33(11):1091-1093. PubMed ID: 36096335
[No Abstract] [Full Text] [Related]
34. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
35. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
Davis AA; Gradishar WJ
Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
[TBL] [Abstract][Full Text] [Related]
36. Flashback Foreword: Preoperative Therapy for Operable Breast Cancer and Clinical Features of Triple-Negative Breast Cancer.
Hudis CA
J Clin Oncol; 2023 Apr; 41(10):1793-1794. PubMed ID: 36989608
[No Abstract] [Full Text] [Related]
37. Positive results for drug combo in I-SPY 2 trial.
Cancer Discov; 2014 Feb; 4(2):OF2. PubMed ID: 24501314
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs].
Hong R; Ma F; Shi X; Li Q; Zhang P; Yuan P; Wang J; Fan Y; Cai R; Li Q; Xu B
Zhonghua Zhong Liu Za Zhi; 2014 Oct; 36(10):788-92. PubMed ID: 25567313
[TBL] [Abstract][Full Text] [Related]
39. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
40. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
